Haemonetics (HAE) Q1 Revenue Falls 4%

Haemonetics (NYSE:HAE), a medical technology company specializing in blood and plasma collection and hospital technologies, reported its financial results for the first quarter of fiscal 2026 on August 7, 2025. The main headlines from the release included GAAP revenue of $321.4 million for Q1 FY2026, which fell short of the analyst estimate by $3.65 million, and non-GAAP earnings per share (EPS) of $1.10, missing by $0.09. GAAP revenue dropped 4.4% from the prior-year period, while adjusted EPS grew 7.8%. Despite the misses, management reaffirmed its full-year guidance, with expectations for organic revenue growth (excluding CSL) and an improved adjusted margin profile in Q4 FY2025. The quarter showed mixed signals, with ongoing business transitions and product line divestitures weighing on visible growth but clear evidence of internal margin expansion and strengthening high-margin business lines. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q4 2025 earnings report. Haemonetics develops and sells products that support plasma collection, blood processing, and hospital procedures. Its portfolio includes systems for automated plasma collection (the NexSys platform), blood management in hospital operating rooms, and devices for closing vascular access sites (VASCADE and related products) used after certain heart procedures.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool